

## Recent advances in the reactions of pyrrolo[2,3-*d*]pyrimidines

Abdel-Rahman Farghaly,\* Nasser Amri, and Ibrahim Radini

Department of Physical Sciences, Chemistry Division, College of Science, Jazan University, P.O. Box. 114, Jazan 45142, Kingdom of Saudi Arabia

Email: [farghaly431@gmail.com](mailto:farghaly431@gmail.com)


Received 10-28-2024

Accepted 12-06-2024

Published on line 12-31-2024

### Abstract

Pyrrolo[2,3-*d*]pyrimidine is one of the important biogenic purine nucleoside analogues with a variety of biological uses. By replacing the N7 atom with a carbon atom, the five-membered ring gains electrons, which makes it possible to add extra substituents at the C7 position. This usually leads to derivatives with higher base pairing in DNA or RNA or more efficient binding to enzymes. It has been discovered that a wide range of 7-deazapurine nucleosides have potent cytotoxic or cytostatic qualities. Most promising are 7-hetaryl-7-deazaadenosines, which are phosphorylated in cancer cells and integrated into RNA (which inhibits proteosynthesis) and DNA (which damages DNA). This review discusses the modern reactions and their different conditions that were carried out on the pyrrolo[2,3-*d*]pyrimidine, whether they occurred in the pyrrole nucleus or the pyrimidine nucleus.




**Keywords:** Pyrrolo[2,3-*d*]pyrimidine, nucleophilic substitution reaction, Buchwald-Hartwig coupling reaction

## Table of Contents

1. Introduction
  2. Reactions of Pyrrolo[2,3-*d*]pyrimidine
    - 2.1. Nucleophilic substitution reactions of 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine
    - 2.2. Reactions on C-6 of pyrrolo[2,3-*d*]pyrimidine
    - 2.3. Synthesis of tricyclic systems containing pyrrolo[2,3-*d*]pyrimidine
    - 2.4. Nucleophilic substitution reactions on N-7 of pyrrole ring
    - 2.5. Reactions on C-5 of pyrrolo[2,3-*d*]pyrimidine
  3. Conclusions
- References

## 1. Introduction

Pyrrole is one of the most common heterocycles found in both plant and animal kingdoms, primarily due to its role as a component of chlorophyll in plants and hemin and vitamin B12 in animals. Pyrrole and its derivatives have demonstrated a range of biological activities, including antibacterial and antifungal properties,<sup>1,2</sup> antitumor effects,<sup>3,4</sup> analgesic capabilities,<sup>5</sup> antitubercular activity,<sup>6-9</sup> anti-inflammatory effects,<sup>10</sup> and significant applications in pharmaceutical research.<sup>11-15</sup> Pyrrolo[2,3-*d*]pyrimidines represent a significant class of heterocyclic compounds, gaining considerable attention due to their wide-ranging biological activities.<sup>16</sup> These fused bicyclic systems are known for their versatility in medicinal chemistry, particularly in the development of novel therapeutic agents,<sup>17</sup> and also referred to as 7-deazapurine, is present in a variety of natural or synthesized compounds that showcase intriguing biological properties.<sup>16</sup> The rigid structure of the pyrrolo[2,3-*d*]pyrimidine scaffold features two hydrogen bond acceptors and one hydrogen bond donor, with five positions (C2, C4, C5, C6, and N7) available for modification. Derivatives of pyrrolo[2,3-*d*]pyrimidine are recognized for their diverse biological activities and potential inhibitors such as tyrosine kinase inhibitors,<sup>17-19</sup> anticancer agents,<sup>20-22</sup> anti-proliferative agents,<sup>23</sup> anti-tubercular agent,<sup>24,25</sup> antimicrobial,<sup>26,27</sup> antiviral,<sup>26</sup> antioxidant,<sup>28</sup> inflammatory activities,<sup>29</sup> and anti-antiviral agent.<sup>30</sup>



**Figure 1.** Selective pyrrolo[2,3-*d*]pyrimidine derivatives as inhibitors of MAP4K4.

Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4), also referred to as HGK (hematopoietic progenitor kinase/germinal center kinase-like kinase), it has recently gained recognition for its


regulatory function in myocardial injury and tissue recovery. Two effective inhibitors of MAP4K4, namely 5,7-diphenyl-3,7-dihydro-4*H*-pyrrolo[2,3-*d*]pyrimidin-4-one (F1386-0303, IC<sub>50</sub> 34 nm) and 5-(4-(2-methoxyethoxy)phenyl)-7-phenyl-3,4a,7,7a-tetrahydro-4*H*-pyrrolo[2,3-*d*]pyrimidin-4-one (DMX-5804, IC<sub>50</sub> 3 nm), have been identified as potent selective inhibitors of MAP4K4. Notably, DMX-5804 demonstrated superior bioavailability *in vivo* compared to F1386-0303.<sup>31</sup> This review emphasizes recent developments in the chemistry of pyrrolo[2,3-*d*]pyrimidine from 2012 to 2024, and is based on searches conducted in SciFinder, Reaxys, and Web of Knowledge.

## 2. Reactions of Pyrrolo[2,3-*d*]pyrimidine

The skeleton of 7-*H*-Pyrrolo[2,3-*d*]pyrimidine (7-deazapurine, 7-DAP) is acknowledged as a significant privileged scaffold that is widely found in various bioactive natural products and drug compounds.<sup>18</sup> This structure has demonstrated remarkable pharmacological properties.


### 2.1. Nucleophilic substitution reactions of 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine

Recently,<sup>33</sup> it was reported that the reaction between chloro derivative **1a** and chloromethyl pivalate **2** was performed in the presence of 60% NaH/THF, yielding the corresponding compound **3**. The reductive amination reaction of *tert*-butyl 4-oxopiperidine-1-carboxylate **4** with 40% methylamine gave compound **6** in satisfactory yield. Nucleophilic substitution reaction of intermediate **3** with *tert*-butyl 4-aminopiperidine-1-carboxylate **5** or **6**, using Et<sub>3</sub>N or DIPEA subsequently afforded the corresponding compounds **7a,b**. Reaction of **7a,b** with HCl/dioxane, *N*-Boc group was removed and the compounds **8a,b** were obtained (Scheme 1).



**Scheme 1.** Protection of *N*-7 of pyrrolo[2,3-*d*]pyrimidine **1a** with chloromethyl pivalate **2**


Reaction<sup>33</sup> of compound **8a,b** with chloroacetyl chloride led to formation of the corresponding compound **9a,b**. The latter Intermediate **9a,b** was subjected to further reaction with various amines at r.t to give the corresponding compounds **10a-e** and **11a-e**. Hydrolysis of latter compound with NaOH/H<sub>2</sub>O solution in methanol gave the compounds **12a-e** and **13a-e**. The key intermediate **8a,b** underwent alkylation reaction with various 2-chloroacetamids at 60°C to afford the intermediates **14a-c** and **15a-c**. Also, hydrolysis of compounds **14a-c** and **15a-c** with NaOH/H<sub>2</sub>O solution in methanol afforded the corresponding derivatives **16a-c** and **17a-c** (Scheme 2).



<b>10b,12b,14b,16b</b>	R = H, NR <sub>1</sub> R <sub>2</sub> = morpholin-1-yl	<b>11c, 13c</b>	R = CH <sub>3</sub> , NR <sub>1</sub> R <sub>2</sub> = pyrrolidin-1-yl
<b>10c,12c</b>	R = H, NR <sub>1</sub> R <sub>2</sub> = pyrrolidin-1-yl	<b>11d, 13d</b>	R = CH <sub>3</sub> , NR <sub>1</sub> R <sub>2</sub> = 4-methylpiperazin-1-yl
<b>10d,12d</b>	R = H, NR <sub>1</sub> R <sub>2</sub> = 4-methylpiperazin-1-yl	<b>11e, 13e</b>	R = CH <sub>3</sub> , NR <sub>1</sub> R <sub>2</sub> = piperidin-1-yl
<b>10e, 12e</b>	R = H, NR <sub>1</sub> R <sub>2</sub> = piperidin-1-yl	<b>14c, 16c</b>	R = H, NR <sub>1</sub> R <sub>2</sub> = 2,5-dimethylphenylamino
<b>11b, 13b,15b,17b</b>	R = CH <sub>3</sub> , NR <sub>1</sub> R <sub>2</sub> = morpholin-1-yl	<b>15c, 17c</b>	R = CH <sub>3</sub> , NR <sub>1</sub> R <sub>2</sub> = 2,5-dimethylphenylamino

### Scheme 2. N-Alkylation reactions of pyrrolo[2,3-d]pyrimidine derivative **8a,b**.


The acylation<sup>33</sup> of compounds **8a,b** with phenyl (2,5-dimethylphenyl)carbamate or various sulfonyl chlorides afforded the corresponding compounds **18a,b**, **20a,b** and **21a,b** respectively (Scheme 3). Finally, deprotection of the methyl pivalate (POM) from the latter compounds **18a,b**, **20a,b** and **21a,b** gave successfully the corresponding compounds **19a,b**, **22a,b**, and **23a,b** as previously described in procedures shown in Scheme 3.



(i) phenyl (2,5-dimethylphenyl)carbamate, Et<sub>3</sub>N, THF, 60°C, 4 h (ii) 1 mol/L NaOH/H<sub>2</sub>O, methanol, r.t., 2 h  
 (iii) various sulfonyl chlorides, Et<sub>3</sub>N, MeCN, 60°C, 1 h

**Scheme 3.** Synthesis of *N*-(1-hydrosulfonylpiperidin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine **22a,b** and **23a,b**.

Bai, H. *et al* mentioned that,<sup>34</sup> the Mitsunobu reaction of 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine **1a** (X = Cl) or 7*H*-pyrrolo[2,3-*d*]pyrimidine **1b** (X = H) with *N*-Boc-4-piperidinol yielded the corresponding pyrrolo[2,3-*d*]pyrimidine derivatives **24**, **25**. Treatment of compound **24** was with ammonia or *N*-methylpiperazine gave the compounds **26** and **27**. Interaction of **24** with *N,N*-dimethylaminoethanol afforded the compound **28**. The Boc group was Deprotected using trifluoroacetic acid (TFA). Nucleophilic substitution reaction of compounds **24-28** gave the corresponding pyrrolo[2,3-*d*]pyrimidine derivatives **29-33** (Scheme 4).




(i) anhydrous THF, *N*-Boc-4-piperidinol, PPh<sub>3</sub>, DIAD, rt, overnight.

(ii) for **31**, NH<sub>3</sub>·H<sub>2</sub>O/dioxane = 2/1 (v/v), 110 °C, 8 h; for **32**, EtOH, DIPEA, 70 °C, reflux, 16 h;

for **33**, THF, NaH, rt, overnight; (iii) DCM, TFA, rt, 1–3 h; (iv) intermediate **34**, K<sub>2</sub>CO<sub>3</sub>, KI, CH<sub>3</sub>CN, 80 °C, overnight.

#### Scheme 4. Synthetic pathways of compounds 29–33.


In continuation to what was mentioned above,<sup>34</sup> the reaction of 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine **1a** with ammonia provided the compound **35**. The iodination reaction of the latter compound **35** with *N*-iodosuccinimide (NIS) led to formation of the derivative **36**. Treatment of compound **36** with *N*-Boc-4-piperidinol through Mitsunobu reaction afforded **37**. Coupling of **37** with boronic acid or ester afforded the corresponding intermediate **38**. Removing of the Boc group from compound **38** was performed in presence of TFA followed by nucleophilic substitution with the intermediates **39a–i** gave the corresponding compounds **40a–I** (Scheme 5).



(i) NH<sub>3</sub>·H<sub>2</sub>O, 130 °C, 6 h; (ii) NIS, THF, rt, 1 h; (iii) anhydrous THF, *N*-Boc-4-piperidinol, PPh<sub>3</sub>, DIAD, rt, overnight; (iv) corresponding boric acid or boric acid ester, (dppf)PdCl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/EtOH/H<sub>2</sub>O = 7/3/4 (v/v/v), 80 °C, overnight; (v) DCM, TFA, rt, 1–3 h; (vi) intermediates **39a-i**, K<sub>2</sub>CO<sub>3</sub>, KI, CH<sub>3</sub>CN, 80 °C, overnight.

### Scheme 5. The synthetic routes of pyrrolo[2,3-*d*]pyrimidine derivatives **40a-i**.

Wang L. *et al* suggested that,<sup>35</sup> Reaction of 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine **1a** with *N,N*-diisopropylethylamine (DIPEA), followed by reaction with PhSO<sub>2</sub>Cl resulted the corresponding compound **41**. Iodination of the latter compound **41** with iodine (I<sub>2</sub>) in the presence of lithium diisopropylamide (LDA) yielded **42**. Furthermore, interaction of the latter derivative **42** with sodium hydroxide removes the -SO<sub>2</sub>Ph and leads to the formation of 4-chloro-6-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (**43**). Compound **43** underwent a Suzuki-Miyaura coupling reaction giving the corresponding pyrrolo[2,3-*d*]pyrimidine derivatives **44**. Compound **44** was activated with DIPEA, followed by reaction with benzylamine or piperazine to obtain the compounds **45a-d**. Whereas, refluxing the compound **44** with DIPEA, followed by the addition of *N*-(2-hydroxyethyl) piperazine resulted to the formation the corresponding derivatives **45e-m** (Scheme 6).



(i)  $\text{PhSO}_2\text{Cl}$ , DIPEA, THF,  $60^\circ\text{C}$  reflux; (ii)  $\text{I}_2$ , LDA, THF,  $-78^\circ\text{C}$ ; (iii)  $\text{NaOH(aq)}$ , MeOH, rt; (iv)  $\text{Pd(dppf)Cl}_2$ ,  $\text{K}_2\text{CO}_3$ ,  $\text{N}_2$ , 1,4-Dioxane,  $80^\circ\text{C}$ ; (v) Benzylamine derivatives, piperazine derivatives, DIPEA, *N*-butanol,  $100^\circ\text{C}$ , reflux; (vi) *N*-(2-hydroxyethyl)piperazine, DIPEA, *N*-butanol,  $100^\circ\text{C}$ , reflux


Comd. No	R <sup>1</sup>	R <sup>2</sup>
45a		
45b		
45c		
45d		

Comd. No	R <sup>2</sup>	Comd. No	R <sup>2</sup>	Comd. No	R <sup>2</sup>
45e		45h		45k	
45f		45i		45l	
45g		45j		45m	

### Scheme 6. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives **45a-m**.

It was found that,<sup>36</sup> Reaction of the choro derivative **1a** and substituted piperazine **46a-c** in the presence of potassium carbonate and DMF gave the corresponding pyrrolo[2,3-d]pyrimidine derivatives **47a-c**. Furthermore, treatment of compounds **47a-c** with substituted acids **48a-d** using EDC.HCl in DMAP and DCM afforded the corresponding compounds **49-50(a-d)** (Scheme 7).






**Scheme 7.** Synthesis of substituted pyrrolo[2,3-d]pyrimidine derivatives **49-51(a-d)**.


## 2.2. Reactions on C-6 of pyrrolo[2,3-d]pyrimidine

In 2023, it was found that,<sup>37</sup> Treatment of aminonitrile derivative **52a,b** with formic acid afforded the corresponding pyrrolo[2,3-d]pyrimidin-4-ones **53a,b**. whereas, the reaction of **52a,b** with acetic acid and hydrochloric acid mixture gave compound **54**. Treatment of compound **53a,b** with an excess of  $POCl_3$  afforded the derivative **55**. While the chlorination of compound **53a,b** using a mixture of  $POCl_3/P_2O_5$  under the microwave technique (MW) gave the corresponding compound **56a,b**. Similarly, treatment of **54** with  $POCl_3/P_2O_5$  under the same conditions yielded compound **57**. It is noteworthy that the chlorination by  $POCl_3$  occurred on C-4 only. Whereas the chlorination using a mixture of  $POCl_3/P_2O_5$  under the microwave technique occurred in the methyl group, C-6 in addition to C-4 (Scheme 8).




**Scheme 8.** Chlorination of pyrrolo[2,3-d]pyrimidine derivatives **53a,b** and/or **54**.

The same authors mentioned that<sup>37</sup> treatment of compounds **56a,b** and **57** with sodium methoxide in methanol gave **58a,b** and **59** respectively. Also, the reaction of pyrrolo[2,3-*d*]pyrimidine **56a,b** and **57** with pyrrolidine in ethanol afforded the corresponding derivatives **60a,b** and **61** respectively. Whereas interaction of **56a** with thiourea in boiling ethanol afforded **62**. Methylation of the latter compound with MeI in ethanol in the presence of NaOH gave the corresponding methylthio derivative **63**. Interaction of **56a,b** and **57** with hydrazine hydrate in boiling ethanol gave the corresponding the hydrazino derivatives **64a,b** and **65** (Scheme 9).




**Scheme 9.** Nucleophilic substitution reactions of chloro derivatives **56** or **57**.

Similarly, reaction of chloro derivatives **56a,b** and/or **57** with *N*-methyl piperazine or morpholine gave a series of substituted pyrrolo[2,3-*d*]pyrimidine **67** and **69** (Scheme 10)<sup>37</sup>.



**Scheme 10.** Nucleophilic substitution reactions of chloro derivatives **56a,b** or **57**.


Treatment<sup>38</sup> of bromo derivative **70** with 4-nitrophenol using DIPEA gave the corresponding compound **71a**. Reduction of the nitro compound **71a** with Fe yielded the amino derivative **72a**. Coupling of the latter compound **72a** with 4-(trifluoromethyl)phenylacetic acid afforded the corresponding acetamide derivative **73a**. Reaction of compound **73a** with different alkyl halides resulted the corresponding pyrrolo[2,3-*d*]pyrimidine derivatives **74a-i**. Compound **71b** was prepared by nucleophilic substitution reaction of compound **70**. Treatment of **71a** with TFA afforded compound **72b**. Coupling of compound **72b** with 4-(trifluoromethyl)phenylacetic acid afforded the corresponding derivative **73b** (Scheme 11).



Reagents and conditions: (a) 4-nitrophenol, DIPEA, NMP, 140 °C, 24 h, 81% (**71a**); *t*-butyl(4-aminophenyl)carbamate, DIPEA, NMP, 140 °C, 24 h, 40% (**71b**); (b) Fe, NH<sub>4</sub>Cl, DMF/EtOH/H<sub>2</sub>O, 100 °C, 20 min, 95% (**72a**); TFA/DCM, rt, 1 h, 96% (**72b**); (c) 4-(trifluoromethyl)phenylacetic acid, HATU, DIPEA, THF, rt, 6 h; (d) RI or RBr, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 10 h, 8%–40%.


**Scheme 11.** Synthesis of compounds **73a,b** and **74a-i**.

Adel, M. *et al* suggested that,<sup>39</sup> the synthesis of 4-chloropyrrolopyrimidine derivative **76** was performed by chlorination of compound **75** with POCl<sub>3</sub>. Reaction of The chloro derivative **76** with 2-fluro-4-amino acetanilide in 1-butanol and drops of conc. HCl gave the amide derivative **77**. Treatment of **77** with 2N HCl provided the amine derivative **78**. When the amine derivative **78** was refluxed with isocyanates, the urea-based pyrrolo[2,3-*d*]pyrimidine derivatives **79a-g** were obtained (Scheme 12).



**Scheme 12.** Treatment of amine compound **78** with isocyanates to afford the compounds **79a-g**.



Treatment<sup>40</sup> of compound **80** with hydrazino derivative **81** afforded the corresponding product **82**. Methylation of compound **82** with CH<sub>3</sub>I and NaH provided the N-methyl derivative **83**. Hydrolysis of **83** afford the corresponding acid **84**. Reaction of **84** with different substituted amines gave the corresponding compounds **85a-f** (Scheme 13).




**Scheme 13.** Synthesis of hydrazinyl compound contained pyrrolo[2,3-*d*]pyrimidine moiety **85a-f**.

The authors mentioned that,<sup>41</sup> reaction of **86** with different amino alcohols, amines, or MeOH gave the corresponding compounds **88a–e**, **89**. Hydrolysis of benzyl ester **86** followed by the amidation in the presence of Me<sub>2</sub>NH and EDCI afforded compound **87**. Nucleophilic substitution reaction of **87** gave compounds **90a–j**. Treatment of compounds **88a–c** with ARS (artesunate) and/or DHA (dihydroartemisinin) gave the corresponding pyrrolo[2,3-*d*]pyrimidine derivatives **91a–e** (Scheme 14).

It was found that,<sup>42</sup> Buchwald Hartwig coupling reaction occurred through the interaction of chloro derivatives of pyrrolo[2,3-*d*]pyrimidine **92a,b** with piperazine derivatives **93a–e** using cesium carbonate and tetrakis (triphenylphosphine) palladium in DMF:H<sub>2</sub>O mixture (3:1) affording the corresponding substituted pyrrolo[2,3-*d*]pyrimidine derivatives (**94a–j**) (Scheme 15).





**Scheme 14.** Reactions on the 6-benzyl carboxylate of pyrrolo[2,3-*d*]pyrimidine **86**.



**Scheme 15.** Buchwald Hartwig coupling reaction of **92a-j**.

Li, S. *et al* found that,<sup>43</sup> Reaction of compound **1a** with methyl aminobenzoates afforded **95a,b**. Hydrolysis of the latter compounds with NaOH led to formation of the corresponding carboxylic acids **96a,b**. Condensation of **96a,b** with different methyl aminoalkanoates produced **97**. Reaction of the latter compound with hydroxyl amine gave the corresponding hydroxamic acid **98**. Furthermore, reaction of **96** with  $\text{NH}_2\text{OTHP}$  yielded the corresponding **99**. Also, reaction of the compound **99** with hydroxyl amine gave hydroxamic acid **100**. On the other hand, reaction of **1a** with tosyl chloride resulted the compound **101**. Treatment of the latter compound **101** with various methyl aminobenzoates afforded **102**. Hydroxamic acids **105** were achieved from compound **102** using the similar methods of synthesizing **100** from **95**. Interaction of intermediates **102** with  $\text{CH}_3\text{I}$  led to formation of **106**. Similarly, hydroxamic acids **109** could be obtained using the similar procedure described above in the synthesis of compound **100** from **95** (Scheme 16).




### Scheme 16. Synthesis of Hydroxamic acids-based pyrrolo[2,3-*d*]pyrimidine **105** and **109**.

Lakkaniga, N. R *et al* reported that,<sup>44</sup> the nucleophilic substitution reaction of 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine **1a,b** with ethyl-2-(4-aminophenyl)acetate (EAPA) gives the ester derivatives **110a,b**. Treatment of the ester **110a,b** with LiOH in THF/ $\text{H}_2\text{O}$  led to formation of corresponding carboxylic acid derivative **111a,b**.



Reaction of **111a,b** with different substituted anilines in the presence of (EDC) afforded the corresponding acetamide derivatives **112-129** (Scheme 17).




No	R	No	R	No	R
112		118		124	
113		119		125	
114		120		126	
115		121		127	
116		122		128	
117		123		129	

**Scheme 17.** Synthesis of pyrrolo[2,3-*d*]pyrimidine substituted-*N*-phenylacetamide derivatives **112-129**.

Furthermore, in continuation to what mentioned above by the same authors,<sup>44</sup> 4-chloro-6-iodo-7H-pyrrolo[2,3-*d*]pyrimidine **130** was prepared as described previously,<sup>45</sup> similarly treatment of compound **130** with ethyl 2-(4-aminophenyl)acetate gave the corresponding ester **131**. Suzuki Miyaura coupling<sup>46</sup> of this intermediate **131** with several boronic acid using Suzuki Miyaura coupling reaction<sup>46</sup> afforded the

corresponding compounds **132-137**. Hydrolysis of latter compounds with LiOH in THF/H<sub>2</sub>O resulted in the formation of corresponding acids **138-143**. Reaction of acids **138-143** with EDC gave the derivatives **144-159** as shown in scheme 18.




No	R	No	R <sup>1</sup>
132, 138		144, 146, 150, 151, 153, 155, 159	
133, 139		145, 149, 152, 154, 158	
134, 140		148, 157	
135, 141		147, 156	
136, 142			
137, 143			

**Scheme 18.** Nucleophilic substitution reaction of 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine **130**.

### 2.3. Synthesis of tricyclic systems containing pyrrolo[2,3-d]pyrimidine

It was found that the reaction of chloro derivative **160a-u** with hydrazine hydrate afforded the corresponding hydrazine derivative **161a-u**, which was allowed to react with sodium nitrite in glacial acetic acid to obtain the


tetrazolopyrrolopyrimidines **162a-u**. Alternatively, treatment of chloro derivative **160a-u** with sodium azide in the presence of the ammonium chloride afforded the tetrazolopyrrolopyrimidines **162a-u** (Scheme19).<sup>47,48</sup>



160-162	R	R <sub>1</sub>	160-162	R	R <sub>1</sub>
<b>a</b>	C <sub>6</sub> H <sub>5</sub>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>l</b>	C <sub>6</sub> H <sub>5</sub>	4-FC <sub>6</sub> H <sub>4</sub>
<b>b</b>	C <sub>6</sub> H <sub>5</sub>	4-BrC <sub>6</sub> H <sub>4</sub>	<b>m</b>	C <sub>6</sub> H <sub>5</sub>	3-Cl-4-FC <sub>6</sub> H <sub>3</sub>
<b>c</b>	C <sub>6</sub> H <sub>5</sub>	4-IC <sub>6</sub> H <sub>4</sub>	<b>n</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	C <sub>6</sub> H <sub>5</sub>
<b>d</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	4-BrC <sub>6</sub> H <sub>4</sub>	<b>o</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>
<b>e</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	4-IC <sub>6</sub> H <sub>4</sub>	<b>p</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	4-FC <sub>6</sub> H <sub>4</sub>
<b>f</b>	4-ClC <sub>6</sub> H <sub>4</sub>	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>q</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	3-Cl-4-FC <sub>6</sub> H <sub>3</sub>
<b>g</b>	4-ClC <sub>6</sub> H <sub>4</sub>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>r</b>	4-ClC <sub>6</sub> H <sub>4</sub>	C <sub>6</sub> H <sub>5</sub>
<b>h</b>	4-ClC <sub>6</sub> H <sub>4</sub>	4-BrC <sub>6</sub> H <sub>4</sub>	<b>s</b>	4-ClC <sub>6</sub> H <sub>4</sub>	4-ClC <sub>6</sub> H <sub>4</sub>
<b>i</b>	4-ClC <sub>6</sub> H <sub>4</sub>	4-IC <sub>6</sub> H <sub>4</sub>	<b>t</b>	4-ClC <sub>6</sub> H <sub>4</sub>	4-FC <sub>6</sub> H <sub>4</sub>
<b>j</b>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	<b>u</b>	4-ClC <sub>6</sub> H <sub>4</sub>	3-Cl-4-FC <sub>6</sub> H <sub>3</sub>
<b>k</b>	C <sub>6</sub> H <sub>5</sub>	4-ClC <sub>6</sub> H <sub>4</sub>			


**Scheme 19.** Synthesis of tetrazolopyrrolopyrimidines **162a-u**.

Interaction<sup>49</sup> of tetrazolopyrrolopyrimidines **163** with zinc in acetic acid obtained the corresponding amino derivative of pyrrolo[2,3-*d*]pyrimidines **165**, which could be prepared by another route by reaction of amino nitrile **164** with formamide (Scheme 20).




**Scheme 20.** Synthesis of amino derivative of pyrrolo[2,3-*d*]pyrimidines **165**.

Rashad *et al.*<sup>50</sup> reported that, Treatment of compounds **166a,b** with sodium azide or thiourea gave the corresponding tetrazole **167a,b** or thione derivative **168a,b** respectively. Reaction of compounds **168a,b** with dimethylsulfate afforded **170a,b** whereas, its reaction with 2-chloroethyl methyl ether gave the corresponding derivatives **169a,b** (Scheme 21).




**Scheme 21.** Some reactions of chloropyrrolo[2,3-*d*]pyrimidine derivative **166a,b**.

Also,<sup>50</sup> Reaction of the hydrazine derivative **171a,b** with some monosaccharides: namely D-ribose or D-glucose in the presence of glacial acetic acid as a catalyst yielded the corresponding hydrazone derivatives **172a,b** and **173a,b**. Heating of **172a,b** and **173a,b** with Ac<sub>2</sub>O at 70 °C afforded products **176a,b** and **177a,b** whereas, when the acetylation reaction was carried out in dry pyridine at room temperature, the products were identified as **174a,b** and **175a,b** (Scheme 22).


Scheme 22. Synthetic routes of compounds **174-177**.

#### 2.4. Nucleophilic substitution reactions on N-7

The nucleobases **178a-d** were silylated with BSA in dry MeCN at r.t to obtain the corresponding derivative **179a-d** and then reacted with D-ribofuranose **180** or L-ribofuranose **181** using TMSOTf (trimethylsilyl trifluoromethanesulfonate) to give the glycosylated intermediates **182a-d** and **183a-d** (Scheme 23).<sup>51</sup>


Scheme 23. Synthesis of glycosylated intermediates **182a-d** and **183a-d**.

Lippa *et al.*<sup>52</sup> Reaction of hydrazino derivative **184a-f** with orthoformates afforded the corresponding triazole derivatives **185a-f** which were reacted with chloropyrrolopyrimidine derivatives **160a-e** yielding the compound **186a-e** (Scheme 24).




**Scheme 24.** Synthesis of substituted pyrrolopyrimidine derivatives **186a-e**.

The synthesis of imidazopiperidines **189a,b** were performed<sup>52</sup> by the condensation of histamine **187** with aldehyde in boiling water to give compound **188**. Reaction of chloropyrrolopyrimidine **160a,b** with amine afforded the final analogs **189a,b** (Scheme 25).




**Scheme 25.** Synthesis of pyrrolo[2,3-*d*]pyrimidine derivatives **189a,b**.

Treatment of pyrrolopyrimidinone derivatives **190a-d** with phosphorus oxychloride gave the corresponding chloropyrrolo pyrimidines **191a-d**. Reaction of chloro derivative 191a-d with thiourea in ethanol led to the formation of the thione derivative **192b-d**. *N*-aryl amines **193a,d** were prepared by the reaction of **191a-d** with aromatic amine derivatives (Scheme 26).<sup>53</sup>




**Scheme 26.** Synthesis of pyrrolo[2,3-*d*]pyrimidinethiones **192b-d** and amino pyrrolo[2,3-*d*]pyrimidines **193a,d**.

Alkylation of pyrrolopyrimidin-2-thiones **194** with  $\alpha$ -halo- carbonyl compounds, gave the compounds **195a,b**.<sup>54</sup> Hydrazinolysis of compounds **195a,b** with hydrazine hydrate, yielded the 2-amino derivative **196a,b** (Scheme 27).



**Scheme 27.** Synthesis of hydrazino derivatives **196a,b**.


Interaction<sup>54</sup> of thione compounds **197** and chloroacetic acid in a mixture of Ac<sub>2</sub>O/AcOH gave the corresponding thiazolopyrimidine derivative **198** which was reacted with aromatic aldehyde in the presence of a catalytic amount of piperidine or triethylamine to afford the corresponding compound **199**. Compound **199** could be obtained directly by the reaction of **197** with chloroacetic acid and aromatic aldehyde in acetic acid and acetic anhydride (Scheme 28).



**Scheme 28.** Reaction of pyrrolopyrimidine **197** with chloroacetic acid to give tricyclic compound **199**.

### 2.5. Reactions on C-5 of pyrrolo[2,3-*d*]pyrimidine

Lal Patel *et al*<sup>27</sup> reported that, esterification of pyrrolo[2,3-*d*]pyrimidine-5-carboxylic acid **200** was done by its reaction with methanol and sulphuric acid to give the corresponding ester **201**. Reaction of the latter compound with hydrazine hydrate afforded hydrazide **202**. Reaction of **200** with  $\text{CS}_2$  in ethanol in the presence of KOH gave the corresponding 1,3,4-oxadiazole-2-thiol **203**. Alkylation of thiol **203** with some alkylating agents afforded the corresponding compounds **206a-e**. Similarly, alkylation of thiol **203** with 2-chloro-*N*-phenylacetamide **204** lead to the formation of the corresponding derivatives **205a-f** (Scheme 29).




**Scheme 29.** Synthesis of 1,3,4-oxadiazole derivatives-based pyrrolo[2,3-*d*]pyrimidine **203**, **205a-f** and **206a-e**.

Zhang, Z. *et al*<sup>55</sup> described that the thiocyanation reaction of compound **207** and  $\text{NH}_4\text{SCN}$  as a thiocyanate source and two equivalent of  $\text{K}_2\text{S}_2\text{O}_8$  as a catalyst, afforded the product **208**. Reaction of **208** with conc. sulfuric acid led to the formation of corresponding thiol **209**. Furthermore, treatment of **208** with 4- $\text{CH}_3\text{PhMgBr}$  gave the thioether derivative **210**. Reaction of **208** with  $\text{NaN}_3$  and  $\text{ZnCl}_2$  as a catalyst in *i*- $\text{PrOH}$




afforded *S*-tetrazole derivative **211**. Trifluoromethylthio ether **212** could be obtained by the reaction of **208** with Prakash's reagent presence of Cs<sub>2</sub>CO<sub>3</sub> as a base (Scheme 30).



**Scheme 30.** Synthetic application of thiocyanated product **208**.


Basic hydrolysis<sup>56</sup> of the aromatic esters **213a-d** gave the acids **214a-d**. The latter compounds **214a-d** were reacted with L-glutamate diesters to afford **215a-d**. Treatment of diesters **215a-d** with 1*N* NaOH, followed by neutralization and acidification yielded the corresponding compounds **216a-d** (Scheme 31).



(i) 1*N* NaOH, rt, 12h, 63-94% (ii) Dimethyl-ordiethyl-L-glutamate (iii) NMM, CDMT, DMF, rt or 40°C, 8-12h, 30-78% or (iv) isobutylchloroformate, TEA, DMF, 0°C, tort, 60h, 61% (v) 1*N* NaOH, rt, 1-24h; (vi) 0-4°C, 1*N* HCl, 19-80%.

**Scheme 31.** Reactions of 5-substitued pyrrolopyrimidine derivatives **213a-d**.


In 2021, Eeda *et al*, reported that,<sup>31</sup> reaction of compound **130** with 2-phenyl-1,3,2-dioxaborinone and cupric acetate in DMF afforded compound **217**. Reaction of **217** with acetic acid and sodium acetate gave the corresponding pyrrolo[2,3-*d*]pyrimidin-4-one **218**. Suzuki–Miyaura cross-coupling reaction of compound **218** with 2-(4-(2-methoxyethoxy)-phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan in the presence of Pd(dppf)Cl<sub>2</sub> gave derivative **219** (DMX-5804) (Scheme 32).



(i) Phenylboronic acid, Cupric acetate, dimethylformamide, 60 °C, 15-33%; (ii) Na-acetate, acetic acid, 100 °C, 15 h; (iii) 2-(4-(2-methoxyethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan, Pd(dppf)Cl<sub>2</sub>, potassium carbonate, microwave reactor, 120 °C, 18% yield.

**Scheme 32.** New synthetic route for synthesis of substituted pyrrolo[2,3-*d*]pyrimidine **219**.


He *et al* reported that,<sup>57</sup> treatment of chloro derivative **1a** with *N*-iodosuccinimide provided the intermediate **130**. Reaction of compound **130** with trimethylsilylethoxymethyl (SEM) gave the corresponding compound **220**. Reaction of the latter compound **220** with various amines and alcohols in the presence of *N,N*-diisopropylethylamine (DIEA) afforded the compounds **221a-c**. Suzuki-Miyaura coupling reaction of **221a-c** with benzo[*d*][1,3]dioxol-5-ylboronic acid and Pd(PPh<sub>3</sub>)<sub>4</sub> as a catalyst generated compounds **222a-c**. Treatment of **222a-c** with TBAF<sub>3</sub>·H<sub>2</sub>O and HCl led to removal of the protective SEM and Boc groups and compound **223a-c** were formed. Reaction of **223a-c** with acryloyl chloride gave the derivatives **224a-c** (Scheme 33).



**Scheme 33.** Synthesis of 4-substitued pyrrolo[2,3-*d*]pyrimidines **224a-c**.

Also,<sup>57</sup> the 4,5-disubstituted pyrrolo[2,3-*d*]pyrimidine derivatives **227a-c** and **228a-c** were prepared following the synthetic procedure of **220a-c**, which are outlined in scheme 34.


Seanego *et al* reported that,<sup>58</sup> reaction of compound **229** with *N*-iodosuccinimide (NIS) afforded the iodinated compound **230**. Treatment of **230** with substituted alkyl bromides or tosylates under basic conditions gave the corresponding compounds **231a-e**. Suzuki-Miyaura coupling reaction of **231a-e** with substituted boronic acids provided the corresponding pyrrolo[2,3-*d*]pyrimidines **232a-e** (scheme 35).



(i) **227a**: DMF, 2-chloroacetyl chloride, DIEA, r.t.; **228a**: DMF, acryloyl chloride, DIEA, r.t.; **227b** and **228b**: DCM, 2-chloroethane-1-sulfonyl chloride, DIEA, r.t.; **227c** and **228c**: DCM, propionic acid, PyBOP, DIEA, r.t. (ii) (3-nitrophenyl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, reflux. (iii) TBAF<sub>3</sub>·H<sub>2</sub>O, DMF, 75<sup>0</sup> C. (iv) Ethyl acetate, HCl in ethyl acetate, r.t.


<b>227a-c</b>	<b>R<sup>1</sup></b>	<b>228a-c</b>	<b>R<sup>1</sup></b>
<b>227a</b>		<b>228a</b>	
<b>227b</b>		<b>228b</b>	
<b>227c</b>		<b>228c</b>	

**Scheme 34.** Synthesis of 4,5-disubstituted pyrrolo[2,3-*d*]pyrimidines **227a-c** and **228a-c**.



i) NIS,  $\text{CHCl}_3$ ,  $60^\circ\text{C}$ , 2 h, 90%; ii) R-X,  $\text{Cs}_2\text{CO}_3$ , DMF,  $70^\circ\text{C}$ , 18 h, 59–79%; iii)  $\text{R}^1\text{-B(OH)}_2$ , 10%  $\text{Pd(PPh}_3)_4$ , aq  $\text{Na}_2\text{CO}_3$ , DME, reflux, 18 h, 35–76% (X = Br or tosylate).


**Scheme 35.** Suzuki-Miyaura coupling reaction of **231a-e** with substituted boronic acids.



(a) Ethyl 4-chloroacetate, NaOAc,  $\text{H}_2\text{O}$ , reflux, 18 h (b) i) 1 N NaOH, RT, 1.5 h, ii) 3 N HCl; (c) Methyl glycinate, EDCI, HOBT,  $\text{Et}_3\text{N}$ , DMF, RT, 5 h

**Scheme 36.** Synthesis 6-substitued pyrrolo[2,3-*d*]pyrimidines **237**.


Treatment of compound **238** with aromatic amine afforded pyrrolo[2,3-*d*]pyrimidine derivatives **239**. The fluorine atom could be introduced in C-6 of pyrrolo[2,3-*d*]pyrimidine by the reaction of with **Selectfluor** in  $\text{CH}_3\text{CN}$  to give fluorine intermediate **240**. Buchwald-Hartwig amination<sup>60</sup> of latter intermediate **240** and aromatic amine produced the corresponding fluorine pyrrolo[2,3-*d*]pyrimidine **241** (Scheme 37).



(i):  $\text{Pd}_2(\text{dba})_3$ , X-phos,  $\text{Cs}_2\text{CO}_3$ , 1,4-dioxane,  $100^\circ\text{C}$ , 18 h; (ii): Select-fluor,  $\text{CH}_3\text{CN}$ ,  $0^\circ\text{C}$ , 1 h, then  $25^\circ\text{C}$ , 18 h; (iii)  $\text{Pd}_2(\text{dba})_3$ , X-phos,  $\text{Cs}_2\text{CO}_3$ , 1,4-dioxane,  $100^\circ\text{C}$ , 18 h.


### Scheme 37. Synthesis of Pyrrolo[2,3-*d*] pyrimidine heterocycle series **242**.

Zhang, Z. *et al.*<sup>61</sup> reported that the photochemical reaction of 4-phenyl-*N*-methylpyrrolo[2,3-*d*]pyrimidine **207** with diphenylphosphine oxide **242** in the presence of benzoyl peroxide (BPO) as an oxidant or using  $\text{Na}_2$ -eosin Y as a photocatalyst afforded the corresponding the C6-phosphorylated product **243** (Scheme 38).




### Scheme 38. Photochemical reaction of pyrrolo[2,3-*d*]pyrimidine **207** with diphenylphosphine oxide **242**.

It was found that,<sup>62</sup> treatment of compound **207** with 3-cyanoiodobenzene and/or 4-cyanoiodobenzene followed by hydrolysis of cyano group afforded the corresponding amide derivatives **244** and **245** respectively. Arylation of compound **207** with 4-iodobenzyl bromide afforded the corresponding the product **246** with hydrolysis of bromomethyl group. Treatment of compound **247** with  $\text{CuCN}$  under the metal coordination reaction resulted in formation of the corresponding compound **248a,b** (Scheme 39).




**Scheme 39.** Reactions of 4-phenylpyrrolo[2,3-*d*]pyrimidine **207**.

Liu, M. *et al.*,<sup>63</sup> found that the arylation of the compound **249** with iodobenzene could be performed using palladium catalysts. Thus, the reaction could be carried out without the addition of the ligands to give the C6-arylated product. Therefore, dioxane was chosen as the preferred solvent in view of its accessibility and a variety of bases (3.0 equiv.), such as LiOH, KOAc, DBU, *N,N*-diisopropylethylamine (DIPEA), and KOH, were compared under parallel reaction conditions (10 mol % of Pd(OAc)<sub>2</sub> and 10 mol % of bpy). Only KOH could give the product **250** in a low yield, LiOH, KOAc, DBU, and DIPEA are practically inert to this arylation. Apparently, a good yield was given in the presence of (3.0 equiv., Cs<sub>2</sub>CO<sub>3</sub>) (Scheme 40).




**Scheme 40.** Synthesis of pyrrolo[2,3-*d*]pyrimidine derivatives **250**.

Pan, C. *et al.*<sup>64</sup> reported that, the reaction of compound **251** with benzoyl azide **252** in a  $[\text{RuCl}_2(\textit{p}\text{-cymene})]_2$  as a catalyst, led to the formation of the desired amidated product **254**. Subsequently, phosphoramidation reaction was achieved via Ru(II) catalysis process using **251** and diphenyl azide phosphate **253** under identical conditions employed for compound **254** to give phosphamide derivatives **255** (Scheme 41).



**Scheme 41.** Ru(II) catalysis process using **251** and diphenyl azide phosphate **253**.

It was reported that,<sup>65</sup> the reaction of compound **256** with triphenylsilane **257** in *t*-BuOH resulted in the formation of the corresponding C-6 silylated product **258**. The reaction yield was found to be sensitive to the loading amounts of LPO and triphenylsilane. The optimal amounts of LPO and triphenylsilane are 4.0 equivalents, respectively, which provided the product **258** in good yield (Scheme 42).



**Scheme 42.** C-H Silylation of heteroarenes **256** with hydrosilanes.



## Conclusions

Pyrrolo[2,3-*d*]pyrimidine derivatives have attracted particular attention to scientists due to the high biological and therapeutic importance of these compounds in all fields, which prompted us to shed light on the modern interactions of these compounds.

## Acknowledgements

The authors gratefully acknowledge the funding of the Deanship of Graduate Studies and Scientific Research, Jazan University, Saudi Arabia, through project number: **(RG24-S030)**

## References

1. Abd El-Hameed, R. H.; Sayed, A. I.; Mahmoud Ali, S.; Mosa, M. A.; Khoder, Z. M.; Fatahala, S. S. Synthesis of novel pyrroles and fused pyrroles as antifungal and antibacterial agents. *J. Enzyme Inhib. Med. Chem.* **2021**, *36* (1), 2183.  
<https://doi.org/10.1080/14756366.2021.1984904>
2. Mane, Y. D.; Surwase, S. M.; Biradar, D. O.; Sarnikar, Y. P.; Jawle, B. H.; Shinde, V. S.; Khade, B. C. Design and Synthesis of Diverse Pyrrole-2-carboxamide Derivatives as a Potent Antibacterial Agents. *J. Heterocycl. Chem.* **2017**, *54* (5), 2627.  
<https://doi.org/10.1002/jhet.2859>
3. Kuznietsova, H.; Dziubenko, N.; Byelinska, I.; Hurmach, V.; Bychko, A.; Lynchak, O.; Milokhov, D.; Khilya, O.; Rybalchenko, V. Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety. *J. Drug Targeting* **2020**, *28* (5), 547.  
<https://doi.org/10.1080/1061186X.2019.1703189>
4. Mateev, E.; Georgieva, M.; Zlatkov, A. Pyrrole as an important scaffold of anticancer drugs: recent advances. *J. Pharm. & Pharm. Sci* **2022**, *25*, 24.  
<https://doi.org/10.18433/jpps32417>
5. El-Sharkawy, K. A.; AlBratty, M. M.; Alhazmi, H. A. Synthesis of some novel pyrimidine, thiophene, coumarin, pyridine and pyrrole derivatives and their biological evaluation as analgesic, antipyretic and anti-inflammatory agents. *Braz. J. Pharm. Sci.* **2019**, *54*, e00153.  
<https://doi.org/10.1590/s2175-97902018000400153>
6. Joshi, S. D.; More, U. A.; Dixit, S. R.; Korat, H. H.; Aminabhavi, T. M.; Badiger, A. M. Synthesis, characterization, biological activity, and 3D-QSAR studies on some novel class of pyrrole derivatives as antitubercular agents. *Med. Chem. Res.* **2014**, *23*, 1123.  
<https://doi.org/10.1007/s00044-013-0709-y>
7. Saha, R.; Alam, M. M.; Akhter, M. Novel hybrid-pyrrole derivatives: their synthesis, antitubercular evaluation and docking studies. *RSC Adv.* **2015**, *5* (17), 12807.  
<https://doi.org/10.1039/c4ra14440f>
8. Surineni, G.; Yogeewari, P.; Sriram, D.; Kantevari, S. Design and synthesis of novel carbazole tethered pyrrole derivatives as potent inhibitors of Mycobacterium tuberculosis. *Bioorg. Med. Chem. Lett.* **2015**, *25* (3), 485.

<https://doi.org/10.1016/j.bmcl.2014.12.040>

9. Liu, P.; Yang, Y.; Ju, Y.; Tang, Y.; Sang, Z.; Chen, L.; Yang, T.; An, Q.; Zhang, T.; Luo, Y. Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against Mycobacterium tuberculosis. *Bioorg. Chem.* **2018**, *80*, 422.  
<https://doi.org/10.1016/j.bioorg.2018.06.004>
10. Paprocka, R.; Pazderski, L.; Mazur, L.; Wiese-Szadkowska, M.; Kutkowska, J.; Nowak, M.; Helmin-Basa, A. Synthesis and Structural Study of Amidrazone Derived Pyrrole-2,5-Dione Derivatives: Potential Anti-Inflammatory Agents. *Molecules* **2022**, *27* (9), 2891.  
<https://doi.org/10.3390/molecules27092891>
11. Petri, G. L.; Spano, V.; Spatola, R.; Holl, R.; Raimondi, M. V.; Barraja, P.; Montalbano, A. Bioactive pyrrole-based compounds with target selectivity. *Eur. j. med. chem.* **2020**, *208*, 112783.  
<https://doi.org/10.1016/j.ejmech.2020.112783>
12. Mohamed, M. S.; Fathallah, S. S. Pyrroles and fused pyrroles: synthesis and therapeutic activities. *Mini-Rev. Org. Chem.* **2014**, *11* (4), 477.  
<https://doi.org/10.2174/1570193x113106660018>
13. Gholap, S. S. Pyrrole: An emerging scaffold for construction of valuable therapeutic agents. *Eur. j. med. Chem.* **2016**, *110*, 13.  
<https://doi.org/10.1016/j.ejmech.2015.12.017>
14. Jeelan Basha, N.; Basavarajaiah, S.; Shyamsunder, K. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. *Mol. Diversity* **2022**, *26* (5), 2915.  
<https://doi.org/10.1007/s11030-022-10387-8>
15. Domagala, A.; Jarosz, T.; Lapkowski, M. Living on pyrrolic foundations—Advances in natural and artificial bioactive pyrrole derivatives. *Eur. j. med. Chem.* **2015**, *100*, 176.  
<https://doi.org/10.1016/j.ejmech.2015.06.009>
16. De Coen, L. M.; Heugebaert, T. S.; García, D.; Stevens, C. V. Synthetic Entries to and Biological Activity of Pyrrolopyrimidines. *Chem Rev* **2016**, *116* (1), 80.  
<https://doi.org/10.1021/acs.chemrev.5b00483>
17. Xia, Z.; Huang, R.; Zhou, X.; Chai, Y.; Chen, H.; Ma, L.; Yu, Q.; Li, Y.; Li, W.; He, Y. The synthesis and bioactivity of pyrrolo [2,3-*d*]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations. *Eur. j. med. Chem.* **2021**, *224*, 113711.  
<https://doi.org/10.1016/j.ejmech.2021.113711>
18. Musumeci, F.; Sanna, M.; Grossi, G.; Brullo, C.; Fallacara, A. L.; Schenone, S. Pyrrolo [2,3-*d*]pyrimidines as kinase inhibitors. *Curr. Med. Chem.* **2017**, *24* (19), 2059.  
<https://doi.org/10.2174/0929867324666170303162100>
19. Abdellatif, K. R.; Bakr, R. B. Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. *Med. Chem. Res.* **2021**, *30*, 31.  
<https://doi.org/10.1007/s00044-020-02656-8>
20. Wang, R.; Chen, Y.; Zhao, X.; Yu, S.; Yang, B.; Wu, T.; Guo, J.; Hao, C.; Zhao, D.; Cheng, M. Design, synthesis and biological evaluation of novel 7*H*-pyrrolo[2,3-*d*] pyrimidine derivatives as potential FAK inhibitors and anticancer agents. *Eur. j. med. Chem.* **2019**, *183*, 111716.  
<https://doi.org/10.1016/j.ejmech.2019.111716>
21. Liu, Y.-M.; Chen, C.-H.; Yeh, T.-K.; Liou, J.-P. Synthesis and Evaluation of Novel 7*H*-pyrrolo-[2,3-*d*]pyrimidine Derivatives As Potential Anticancer Agents. *Future Med. Chem.* **2019**, *11* (9), 959.  
<https://doi.org/10.4155/fmc-2018-0564>

22. Bandi, S. R.; Kavitha, N.; Nukala, S. K.; Thirukovela, N. S.; Manchal, R.; Palabindela, R.; Narsimha, S. Synthesis and biological evaluation of novel [1,2,3]triazolo-pyrrolo [1,2-a]pyrido [4,3-d]pyrimidines as EGFR targeting anticancer agents. *J. Mol. Struct.* **2023**, *1274*, 134378.  
<https://doi.org/10.1016/j.molstruc.2022.134378>
23. Lee, J.-H.; El-Damasy, A. K.; Seo, S. H.; Gadhe, C. G.; Pae, A. N.; Jeong, N.; Hong, S.-S.; Keum, G. Novel 5, 6-disubstituted pyrrolo [2,3-d] pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study. *Bioorg. & Med. Chem.* **2018**, *26* (21), 5596.  
<https://doi.org/10.1016/j.bmc.2018.10.004>
24. Jesumoroti, O. J.; Beteck, R. M.; Jordaan, A.; Warner, D. F.; Legoabe, L. J. Exploration of 4-aminopyrrolo[2,3-d]pyrimidine as antitubercular agents. *Mol. Diversity* **2023**, *27* (2), 753.  
<https://doi.org/10.1007/s11030-022-10453-1>
25. Raju, K. S.; AnkiReddy, S.; Sabitha, G.; Krishna, V. S.; Sriram, D.; Reddy, K. B.; Sagurthi, S. R. Synthesis and biological evaluation of 1H-pyrrolo [2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents. *Bioorg. & med. chem. lett.* **2019**, *29* (2), 284.  
<https://doi.org/10.1016/j.bmcl.2018.11.036>
26. Hilmy, K.; Tag, M.; Aish, E.; Elsafty, M.; Attia, H. Synthesis and Biological Evaluation of Pyrrolo[2,3-d] pyrimidine Derivatives as a Novel Class of Antimicrobial and Antiviral Agents. *Russ. J. Org. Chem.* **2021**, *57*, 430.  
<https://doi.org/10.1134/S1070428021030155>
27. Lal Patel, J.; Kumar Sureddy, N.; Boddupalli, M.; Chedupaka, R.; Papisetti, V.; SP, M.; Penta, S. Design, Synthesis, in Vitro, and in Silico Evaluations of 1, 3, 4-Oxadiazole Derivatives Linked to the Pyrrolo [2,3-d]pyrimidine Moieties as Potent Antimicrobial Targets. *Chem. Select* **2024**, *9* (23), e202400117.  
<https://doi.org/10.1002/slct.202400117>
28. Al-Mutairi, A. A.; Hafez, H. N.; El-Gazzar, A.-R. B.; Mohamed, M. Y. Synthesis and antimicrobial, anticancer and anti-oxidant activities of novel 2, 3-dihydropyrrolo [2,3-d] pyrimidine-4-one and pyrrolo [2,1-b][1, 3] benzothiazole derivatives via microwave-assisted synthesis. *Molecules* **2022**, *27* (4), 1246.  
<https://doi.org/10.3390/molecules27041246>
29. AbdEl-Azim, M. H.; Aziz, M. A.; Mouneir, S. M.; EL-Farargy, A. F.; Shehab, W. S. Ecofriendly synthesis of pyrano[2,3-d]pyrimidine derivatives and related heterocycles with anti-inflammatory activities. *Arch. Pharmazie* **2020**, *353* (9), 2000084.  
<https://doi.org/10.1002/ardp.202000084>
30. Soto-Acosta, R.; Jung, E.; Qiu, L.; Wilson, D. J.; Geraghty, R. J.; Chen, L. 4, 7-Disubstituted 7 H-Pyrrolo[2,3-d] pyrimidines and Their Analogs as Antiviral Agents against Zika Virus. *Molecules* **2021**, *26* (13), 3779.  
<https://doi.org/10.3390/molecules26133779>
31. Eeda, V.; Awasthi, V. Catalyst-Free and Scalable Process for Synthesis of Novel MAP4K4 Inhibitor DMX-5804 and Its Glyco-Conjugates. *Org. Process Res. & Develop.* **2021**, *25* (7), 1658.  
<https://doi.org/10.1021/acs.oprd.1c00130>
32. Fiedler, L. R.; Chapman, K.; Xie, M.; Maifoshie, E.; Jenkins, M.; Golphoroush, P. A.; Bellahcene, M.; Nosedá, M.; Faust, D.; Jarvis, A. MAP4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo. *Cell Stem Cell* **2019**, *24* (4), 579-591. e512.  
<https://doi.org/10.1016/j.stem.2019.01.013>
33. Zhang, J.; Xing, S.; Cui, J.; Wei, X.; Cao, Z.; Shao, B.; Jiang, N.; Zhai, X. Structure-guided design of potent JAK1-selective inhibitors based on 4-amino-7H-pyrrolo [2,3-d] pyrimidine with anti-inflammatory efficacy. *Arch. Pharm* **2024**, *357* (4), 2300591.

<https://doi.org/10.1002/ardp.202300591>

34. Bai, H.; Yang, Z.; Lei, H.; Wu, Y.; Liu, J.; Yuan, B.; Ma, M.; Gao, L.; Zhang, S.-Q.; Xin, M. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors. *Eur. J. Med. Chem.* **2024**, *268*, 116226.  
<https://doi.org/10.1016/j.ejmech.2024.116226>.
35. Wang, L.; Zhang, X.; Huang, Y.; Xu, Z.; Ni, D.; Li, X.; Ke, Y.; Xiao, W.; Zhang, R. Design and synthesis of novel pyrrolo [2,3-d]pyrimidine derivatives as potent JAK3 and SYK dual inhibitors. *J. Mol. Struct.* **2024**, *1318*, 139213.  
<https://doi.org/10.1016/j.molstruc.2024.139213>
36. Zala, A. R.; Tiwari, R.; Naik, H. N.; Ahmad, I.; Patel, H.; Jauhari, S.; Kumari, P. Design and synthesis of pyrrolo [2,3-d]pyrimidine linked hybrids as  $\alpha$ -amylase inhibitors: Molecular docking, MD simulation, ADMET and antidiabetic screening. *Molecular Diversity* **2024**, *28* (3), 1681-1695.  
<https://doi.org/10.1007/s11030-023-10683-x>
37. Sroor, F. M.; Tohamy, W. M.; Zoheir, K. M.; Abdelazeem, N. M.; Mahrous, K. F.; Ibrahim, N. S. Design, synthesis, in vitro anticancer, molecular docking and SAR studies of new series of pyrrolo [2,3-d] pyrimidine derivatives. *BMC Chem.* **2023**, *17* (1), 106.  
<https://doi.org/10.1186/s13065-023-01014-0>
38. Liang, X.; Wang, C.; Wang, B.; Liu, J.; Qi, S.; Wang, A.; Liu, Q.; Deng, M.; Wang, L.; Liu, J. Discovery of Pyrrolo [2,3-d] pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. *Eur. J. Med. Chem.* **2022**, *243*, 114782.  
<https://doi.org/10.1016/j.ejmech.2022.114782>
39. Adel, M.; Abouzid, K. A. New fluorinated diarylureas linked to pyrrolo [2, 3-d] pyrimidine scaffold as VEGFR-2 inhibitors: Molecular docking and biological evaluation. *Bioorg. Chem.* **2022**, *127*, 106006.  
<https://doi.org/10.1016/j.bioorg.2022.106006>
40. Mao, W.; Wu, H.; Guo, Q.; Zheng, X.; Wei, C.; Liao, Y.; Shen, L.; Mi, J.; Li, J.; Chen, S. Synthesis and evaluation of hydrazinyl-containing pyrrolo [2,3-d] pyrimidine series as potent, selective and oral JAK1 inhibitors for the treatment of rheumatoid arthritis. *Bioorg & Med. Chem. Lett.* **2022**, *74*, 128905.  
<https://doi.org/10.1016/j.bmcl.2022.128905>
41. Ding, J.; Liu, T.; Zeng, C.; Li, B.; Ai, Y.; Zhang, X.; Zhong, H. Design, synthesis, and anti-breast-cancer activity evaluation of pyrrolo(pyrido)[2,3-d]pyrimidine derivatives. *Chem. Heterocycl. Compd.* **2022**, *58* (8), 438.  
<https://doi.org/10.1007/s10593-022-03110-w>
42. Aggile, K.; Napoleon, A. A. Synthesis of Novel Substituted Piperazin-1-yl-7H-Pyrrolo [2,3-d] Pyrimidines for CN Bond Formation via Buchwald Hartwig Coupling Reaction. *Polycyclic Aromat. Compd* **2022**, *42* (10), 6836-6845.  
<https://doi.org/10.1080/10406638.2021.1991394>
43. Li, S.; Zhao, C.; Zhang, G.; Xu, Q.; Liu, Q.; Zhao, W.; Chou, C. J.; Zhang, Y. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. *Bioorg. Chem.* **2021**, *116*, 105278.  
<https://doi.org/10.1016/j.bioorg.2021.105278>
44. Lakkaniga, N. R.; Gunaganti, N.; Zhang, L.; Belachew, B.; Frett, B.; Leung, Y.-K.; Li, H.-y. Pyrrolo [2, 3-d] pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation *Eur. J. Med. Chem* **2020**, *206*, 112691.  
<https://doi.org/10.1016/j.ejmech.2020.112691>

45. Kaspersen, S. J.; Han, J.; Nørsett, K. G.; Rydså, L.; Kjøbli, E.; Bugge, S.; Bjørkøy, G.; Sundby, E.; Hoff, B. H. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. *Eur. J. Pharm. Sci.* **2014**, *59*, 69.  
<https://doi.org/10.1016/j.ejps.2014.04.011>
46. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. *Chem. Rev.* **1995**, *95* (7), 2457.  
<https://doi.org/10.1021/cr00039a007>
47. Dave, C. G.; Shah, R. D. Synthesis of 7H-tetrazolo [1,5-c] pyrrolo [3,2-e] pyrimidines and their reductive ring cleavage to 4-aminopyrrolo [2,3-d]pyrimidines. *J. Heterocycl. Chem.* **1998**, *35* (6), 1295.  
<https://doi.org/10.1002/jhet.5570350609>
48. Dave, C. G.; Shah, R. D. Annellation of Triazole and Tetrazole Systems onto Pyrrolo[2,3-d]pyrimidines: Synthesis of Tetrazolo [1,5-c]pyrrolo[3,2-e]pyrimidines and Triazolo[1,5-c]pyrrolo[3,2-e]pyrimidines as Potential Antibacterial Agents. *Molecules* **2002**, *7* (7), 554.  
<https://doi.org/10.3390/70700554>
49. Dave, C.; Shah, P.; Upadhyaya, S. Pyrrolo[2,3-d]pyrimidines. Synthesis and Reaction of 2-Amino-3-cyanopyrroles. *ChemInform* **1988**, *19* (22).  
<https://doi.org/10.1002/chin.198822218>
50. Rashad, A. E.; Mohamed, M. S.; Zaki, M. E.; Fatahala, S. S. Synthesis and biological evaluation of some pyrrolo[2,3-d]pyrimidines. *Arch. Pharm. Chem. Life Sci.* **2006**, *339* (12), 664.  
<https://doi.org/10.1002/ardp.200600055>
51. Seela, F.; Ming, X. 7-Functionalized 7-deazapurine  $\beta$ -d and  $\beta$ -l-ribonucleosides related to tubercidin and 7-deazainosine: glycosylation of pyrrolo [2,3-d] pyrimidines with 1-O-acetyl-2, 3, 5-tri-O-benzoyl- $\beta$ -d or  $\beta$ -l-ribofuranose. *Tetrahedron* **2007**, *63* (39), 9850.  
<https://doi.org/10.1016/j.tet.2007.06.107>
52. Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffman, G. S.; Pandit, J.; Robinson, S.; Wei, L.; Kozina, E.; Marr, E. S. Synthesis and structure based optimization of novel Akt inhibitors. *Bioorg & Med. Chem. Lett.* **2008**, *18* (11), 3359.  
<https://doi.org/10.1016/j.bmcl.2008.04.034>
53. Mohamed, M. S.; El-Domany, R. A.; Abd El-Hameed, R. H. Synthesis of certain pyrrole derivatives as antimicrobial agents. *Acta pharm.* **2009**, *59* (2), 145.  
<https://doi.org/10.2478/v10007-009-0016-9>
54. Mohamed, M. S.; Kamel, R.; Fatahala, S. S. Synthesis and biological evaluation of some thio containing pyrrolo[2,3-d]pyrimidine derivatives for their anti-inflammatory and anti-microbial activities. *Eur. J. Med. Chem.* **2010**, *45* (7), 2994.  
<https://doi.org/10.1016/j.ejmech.2010.03.028>
55. Zhang, Z.; Shen, C.; Tang, J.; Wang, J.; Cui, X.; Zhang, X.  $K_2S_2O_8$  promoted C–H direct thiocyanation of pyrrolo[2,3-d]pyrimidine derivatives with ammonium thiocyanate. *Tetrahedron* **2024**, *159*, 134008.  
<https://doi.org/10.1016/j.tet.2024.134008>
56. Kaku, K.; Ravindra, M. P.; Tong, N.; Choudhary, S.; Li, X.; Yu, J.; Karim, M.; Brzezinski, M.; O'Connor, C.; Hou, Z. Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport. *ACS Med. Chem. Lett.* **2023**, *14* (12), 1682.  
<https://doi.org/10.1021/acsmchemlett.3c00326>

57. He, L.; Zhang, J.; Ling, Z.; Zeng, X.; Yao, H.; Tang, M.; Huang, H.; Xie, X.; Qin, T.; Feng, X. Structural optimizations on the 7*H*-pyrrolo [2,3-*d*]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis. *Bioorg. Chem.* **2024**, 107499.  
<https://doi.org/10.1016/j.bioorg.2024.107499>
58. Seanego, T. D.; Chavalala, H. E.; Henning, H. H.; de Koning, C. B.; Hoppe, H. C.; Ojo, K. K.; Rousseau, A. L. 7*H*-Pyrrolo[2,3-*d*]pyrimidine-4-amines as Potential Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinases. *ChemMedChem* **2022**, 17 (22), e202200421.  
<https://doi.org/10.1002/cmdc.202200421>
59. Zhang, Y.; Luo, Z.; Guo, L.; Zhang, H.; Su, T.; Tan, Z.; Ren, Q.; Zhang, C.; Fu, Y.; Xing, R. Discovery of novel tumor-targeted near-infrared probes with 6-substituted pyrrolo[2,3-*d*]pyrimidines as targeting ligands. *Eur. J. Med. Chem.* **2023**, 262, 115914.  
<https://doi.org/10.1016/j.ejmech.2023.115914>
60. Chen, C.; Wang, Y.; Hu, M.-Q.; Li, H.; Chen, X.; Qiang, G.; Sun, Y.; Zhu, Y.; Li, B. Discovery of pyrrolo [2,3-*d*] pyrimidine-based molecules as a Wee1 inhibitor template. *Bioorg. & Med. Chem. Lett.* **2022**, 75, 128973.  
<https://doi.org/10.1016/j.bmcl.2022.128973>
61. Zhang, Z.; Liu, M.; Liu, M.; Pan, C.; Mao, Z.; Zhang, X. Visible-Light-Induced Highly Site-Selective Direct C–H Phosphorylation of Pyrrolo[2,3-*d*]pyrimidine Derivatives with H-Phosphine Oxides. *J. Org. Chem.* **2024**, 89 (5), 2996.  
<https://doi.org/10.1021/acs.joc.3c02416>
62. Liu, M.; Mao, Z.; Jiang, Y.; Zhang, Z.; Zhang, X. Pd-catalyzed Site-selective direct arene C H arylation of Pyrrolo [2, 3-*d*] pyrimidine derivatives with aryl iodides. *Tetrahedron Lett.* **2022**, 96, 153754.  
<https://doi.org/10.1016/j.tetlet.2022.153754>
63. Liu, M.; Qiu, B.; Zhang, Z.; Zheng, Y.; Yuan, J.; Li, H.; Zhang, X. Ligand-Enabled C6-Selective C–H Arylation of Pyrrolo [2,3-*d*]Pyrimidine Derivatives with Pd Catalysts: An Approach to the Synthesis of EGFR Inhibitor AEE-788. *J. Org. Chem.* **2024**, 89, 11, 8023.  
<https://doi.org/10.1021/acs.joc.4c00667>
64. Pan, C.; He, C.; Wang, J.; Tang, J.; Zhang, X. Ruthenium-catalysed direct C–H amidation of 4-aryl-pyrrolo[2, 3-*d*]pyrimidines with acyl/phosphoryl azides. *Org. & Biomol. Chem.* **2024**, 22 (6), 1181.  
<https://doi.org/10.1039/D3OB01946B>
65. Liu, M.; Li, N.; Zhu, Q.; Zhang, Z.; Liu, M.; Mao, Z.; Zhang, X. Free radical-promoted direct C–H silylation of pyrrolo [2, 3-*d*] pyrimidine derivatives with hydrosilanes. *Tetrahedron* **2024**, 155, 133912.  
<https://doi.org/10.1016/j.tet.2024.133912>

## Authors' Biographies



**Abdel-Rahman Farghaly**, is professor of Organic Chemistry at Department of Chemistry, Faculty of Science, Assiut University, Egypt, he has received his B.Sc. (1989) and M.Sc. (1994) in Organic Chemistry at faculty of Science, Assiut University, he got his Ph. D through Chanel Scholarship between University of Assiut and University of Vienna (2001). His Ph.D. thesis has been performed in the Department of Drug and Natural Product Synthesis, Faculty of Life Sciences, University of Vienna, Vienna- Austria in the period from 15/10/1999 to 15/10/2001. He is interested in the field of Medicinal Chemistry, especially in the synthesis of new compounds focusing on a particular heterocyclic ring system which appears of considerable pharmaceutical interest and total synthesis of natural Product. He is working as professor in the Department of Physical Sciences, Chemistry Division, College of Science, Jazan University, Kingdom of Saudi Arabia till now.



**Nasser Amri** is Assistant professor of organic chemistry at Jazan University. He received his B.S. degree in chemistry in 2012 at Jazan University. Subsequently, he started his work at the same university. Later he moved to the USA and obtained his M.S. degree in 2016 at Emporia State University. In 2017, he started his PhD work under the supervision of Prof. T. Wirth at Cardiff University in the area of flow electrochemistry and obtained his degree in 2022. His main research interest concern flow chemistry including electrochemistry performed in micro reactors.



**Ibrahim Radini** is professor of Organic Chemistry the Department of Physical Sciences, Chemistry Division, College of Science, Jazan University, Kingdom of Saudi Arabia. He got Doctor of Philosophy in Chemistry, University of Hull, UK April 2011, Master of Science in Chemistry, Western Illinois University, USA May 2004. Bachelor of Education in Science major in Chemistry, King Saud University, Saudi Arabia, May 1995.

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)